title: Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression.
abstract: Recent data have suggested that rituximab is an active agent for the treatment of Waldenstrom's macroglobulinemia (WM). However, the patients that are more likely to benefit have not been clearly defined. In order to address this question we evaluated 52 patients who were treated with single-agent rituximab in the context of prospective studies. Several clinical and laboratory variables were assessed for their correlation with response and time to progression. Twenty-three (44%) patients achieved a partial response after treatment with rituximab. Previously untreated and pretreated patients had the same probability for response. Higher response rates were noted in patients with serum monoclonal protein < 40 g/l, with serum albumin > or = 35 g/l and with kappa light chain. The median time to progression for all patients was 13.8 months. A multivariate analysis indicated that elevated serum monoclonal protein levels and low serum albumin were the dominant variables associated with shorter progression. Presence of two, one or none of these adverse prognostic factors was associated with time to progression of 3.6 months, 11 months and more than 40 months, respectively. We conclude that rituximab is an effective treatment modality for patients with WM. Patients with both low levels of monoclonal protein and normal albumin are the best candidates for treatment with standard dose rituximab.
authors.affiliation: Department of Clinical Therapeutics, University of Athens School of Medicine, Greece. mdimop@med.uoa.gr
authors.forename: Meletios A
authors.initials: MA
authors.lastname: Dimopoulos
authors.forename: Raymond
authors.initials: R
authors.lastname: Alexanian
authors.forename: Dimitra
authors.initials: D
authors.lastname: Gika
authors.forename: Athanasios
authors.initials: A
authors.lastname: Anagnostopoulos
authors.forename: Constantinos
authors.initials: C
authors.lastname: Zervas
authors.forename: Athanassios
authors.initials: A
authors.lastname: Zomas
authors.forename: Marie C
authors.initials: MC
authors.lastname: Kyrtsonis
authors.forename: Nicolaos
authors.initials: N
authors.lastname: Anagnostopoulos
authors.forename: Gerassimos A
authors.initials: GA
authors.lastname: Pangalis
authors.forename: Donna M
authors.initials: DM
authors.lastname: Weber
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D001798:Blood Proteins / Q000032:analysis / Q000187:drug effects; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012074:Remission Induction; D012307:Risk Factors; D000069283:Rituximab; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001798:Blood Proteins; D000069283:Rituximab